Evidentiary labels for this page: [Documented Official Policy] and [Active Policy Debate]. Content is sourced from official HHS announcements, the CDC immunization schedule, and documented institutional responses.
The January 2026 Policy Shift
On January 5, 2026, the Department of Health and Human Services (HHS) announced a significant reorganization of the U.S. childhood immunization schedule, reorganizing how certain vaccines are categorized and recommended. Acting CDC Director Jim O'Neill signed a decision memorandum following a presidential directive to review international best practices from peer developed nations.
The revised schedule introduced a three-tier framework that reduced the number of diseases targeted by routine universal recommendations from 17 to 11, while maintaining access to all previously recommended vaccines through insurance coverage.
Understanding the Three-Tier Framework
The 2026 schedule organizes federal vaccine recommendations into three distinct categories. It is important to distinguish between federal recommendations and state mandates: while the federal government sets the recommended schedule, individual states determine which vaccines are required for school entry.
Tier 1: Recommended for All Children
These vaccines remain universally recommended for the general pediatric population. The clinical guidance for these vaccines is unchanged from the prior schedule.
Tier 2: Recommended for High-Risk Groups or Populations
These vaccines are recommended for individuals with specific medical conditions, environmental exposure risks, or risk of disease transmission to others. Healthcare providers determine eligibility based on documented risk criteria.
Tier 3: Shared Clinical Decision-Making (SCDM)
These vaccines are no longer universally recommended for all children. Instead, the decision to vaccinate is based on an individual consultation between a parent or guardian and a healthcare provider, considering the child's health status, exposure risk, and clinical judgment.
The 2026 Vaccine Categorization
The following table summarizes the three-tier structure announced on January 5, 2026:
| Category | Vaccines Included | Notes |
|---|---|---|
| Tier 1 — Recommended for All | DTaP, Hib, PCV (Pneumococcal), Polio (IPV), MMR, HPV, Varicella (Chickenpox) | 11 diseases covered. HPV dosing reduced from 2-3 doses to 1 dose based on evolving evidence. |
| Tier 2 — High-Risk Groups Only | RSV, Hepatitis A, Hepatitis B, Dengue, Meningococcal ACWY, Meningococcal B | Risk criteria defined by CDC guidelines. Eligibility determined by healthcare provider. |
| Tier 3 — SCDM Framework | Rotavirus, COVID-19, Influenza, Meningococcal Disease, Hepatitis A, Hepatitis B | Decision based on individual clinical consultation between parent/guardian and provider. |
Important note: Meningococcal disease, Hepatitis A, and Hepatitis B are dually categorized, appearing in both the high-risk and SCDM tiers depending on age, medical history, and exposure risk.
What Did Not Change
The following elements of U.S. immunization policy remain unchanged under the 2026 reorganization:
- Eleven diseases remain universally recommended for all children (Tier 1).
- All vaccines previously on the schedule remain available to any family that wants them.
- Insurance coverage is maintained across all three tiers through ACA plans, Medicaid, CHIP, and the Vaccines for Children program.
- The clinical safety and efficacy evidence for all vaccines on the schedule was not revised or disputed by the HHS announcement.
- State school-entry vaccine requirements remain governed by state law, not federal recommendation categories.
Insurance and Coverage Policy
Current Coverage Guarantee
According to the January 2026 HHS Fact Sheet, all vaccines recommended by the CDC as of December 31, 2025 — including those moved to the SCDM tier — remain covered by the Affordable Care Act (ACA), Medicaid, the Children's Health Insurance Program (CHIP), and the Vaccines for Children (VFC) program. Families are not required to purchase any previously covered vaccine out of pocket.
[Active Policy Debate] Long-Term Coverage Questions
While current coverage is guaranteed through existing federal requirements, policy analysts are monitoring whether the reclassification of certain vaccines as SCDM may affect future insurance rate filings or reimbursement models. This area remains in active development and readers should monitor primary sources for updates.
What SCDM Means in Practice
Shared Clinical Decision-Making is a formal regulatory category used when federal authorities determine that the net clinical benefit of a vaccine may vary based on an individual's specific health profile, risk of exposure, or personal circumstances. Under SCDM, parents and guardians are encouraged to discuss the risk-benefit profile for their child's specific circumstances with their healthcare provider.
SCDM is not a clinical directive to avoid vaccination, nor a recommendation against it. It shifts the default from a population-level recommendation to an individualized clinical conversation.
For more on evaluating vaccine risk-benefit decisions, see our Benefit-Risk Framework page.
Institutional Context: The Policy Debate
The January 2026 reorganization is a subject of significant professional and institutional debate. This section documents the principal positions.
Supporting Arguments
Proponents of the changes, including HHS leadership, argue that the prior U.S. schedule was an outlier among developed nations in the number of universally recommended vaccines. They contend that a more focused core schedule improves clarity, supports informed consent, and aligns with international practices. HHS stated that the revision was based on a comparative review of 20 peer nations and that many countries achieving strong child health outcomes recommend fewer routine vaccines.
Institutional Opposition
Over 200 health organizations, led by the Infectious Diseases Society of America (IDSA) and the American Academy of Pediatrics (AAP), formally opposed the changes. Their stated concerns include: the reclassification was not based on new clinical evidence regarding the safety or efficacy of the affected vaccines; reduced uptake could lead to localized outbreaks and erosion of population-level protection; the newly constituted ACIP was not afforded the opportunity to publicly discuss the schedule before it was announced; and SCDM reclassification may create confusion about liability protections under the Vaccine Injury Compensation Program.
This policy area remains in active development. Readers should consult primary sources including the Federal Register, CDC.gov, and official HHS communications for the most current information.
Sources and Citations
- HHS Press Release: CDC Acts on Presidential Memorandum to Update Childhood Immunization Schedule (January 5, 2026) — https://www.hhs.gov/press-room/cdc-acts-presidential-memorandum-update-childhood-immunization-schedule.html
- HHS Fact Sheet: CDC Childhood Immunization Recommendations — https://www.hhs.gov/press-room/fact-sheet-cdc-childhood-immunization-recommendations.html
- IDSA and Over 200 Health Organizations Urge Congressional Oversight — https://www.idsociety.org/news--publications-new/articles/2026/IDSA-and-over-200-health-organizations-urge-congress-to-conduct-oversight-of-changes-to-vaccine-schedule/